Latest Patent Filings News

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.

Decidr AI Industries has successfully completed a $15 million placement to fund key product development and expansion initiatives, reinforcing its lead in the agentic AI sector.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

TG Metals has expanded its Van Uden gold resource to 270,800 ounces with a 120% increase in indicated ounces, discovered new mineralisation 550m south, and filed a lithium processing patent at Lake Johnston.

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.